Search

Your search keyword '"Capodanno, D"' showing total 743 results
Start Over Author "Capodanno, D" Language english

Refine your results

743 results on '"Capodanno, D"'

3. European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1—epidemiology, pathophysiology, and diagnosis

Author

Baigent, C., Windecker, S., Andreini, D., Arbelo, E., Barbato, E., Bartorelli, A.L., Baumbach, A., Behr, E.R., Berti, S., Bueno, H., Capodanno, D., Cappato, R., Chieffo, A., Collet, J.P., Cuisset, T., Simone, G. de, Delgado, V., Dendale, P., Dudek, D., Edvardsen, T., Elvan, A., Gonzalez-Juanatey, J.R., Gori, M., Grobbee, D., Guzik, T.J., Halvorsen, S., Haude, M., Heidbuchel, H., Hindricks, G., Ibanez, B., Karam, N., Katus, H., Klok, F.A., Konstantinides, S.V., Landmesser, U., Leclercq, C., Leonardi, S., Lettino, M., Marenzi, G., Mauri, J., Metra, M., Morici, N., Mueller, C., Petronio, A.S., Polovina, M.M., Potpara, T., Praz, F., Prendergast, B., Prescott, E., Price, S., Pruszczyk, P., Rodriguez-Leor, O., Roffi, M., Romaguera, R., Rosenkranz, S., Sarkozy, A., Scherrenberg, M., Seferovic, P., Senni, M., Spera, F.R., Stefanini, G., Thiele, H., Tomasoni, D., Torracca, L., Touyz, R.M., Wilde, A.A., Williams, B., Task Force Management Covid-19 Eur, Nuffield Department of Population Health [Oxford], University of Oxford, Bern University Hospital [Berne] (Inselspital), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Nutrition, obésité et risque thrombotique (NORT), Institut National de la Recherche Agronomique (INRA)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Paris-Centre de Recherche Cardiovasculaire (PARCC (UMR_S 970/ U970)), Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), CHU Pontchaillou [Rennes], Laboratoire Traitement du Signal et de l'Image (LTSI), Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM), University of Glasgow, Amsterdam UMC - Amsterdam University Medical Center, University College of London [London] (UCL), Baigent, C, Cardiology, Task Force for the management of COVID-19 of the European Society of, Cardiology, ACS - Heart failure & arrhythmias, Task Force Management Covid-19 Eur, University of Oxford [Oxford], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPC), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM), delgado, victoria/0000-0002-9841-2737, BUENO, HECTOR/0000-0003-0277-7596, Karam, Nicole/0000-0002-3861-6914, Baigent, Colin/0000-0003-4856-7420, Behr, Elijah/0000-0002-8731-2853, Williams, Bryan/0000-0002-8094-1841, Rodriguez-Leor, Oriol/0000-0003-2657-5657, BUENO, HECTOR/0000-0003-0277-7596, Rodriguez-Leor, Oriol/0000-0003-2657-5657, Williams, Bryan/0000-0002-8094-1841, Karam, and Nicole/0000-0002-3861-6914

Subjects
ACE2, Arrhythmias, Biomarkers, Cardiogenic shock, COVID-19, Myocardial, medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), Physiology, Myocardial injury, Myocarditis, Non-invasive imaging, Humans, Pandemics, Prospective Studies, Cardiology, Cardiovascular Diseases, Settore MED/11 - Malattie dell'Apparato Cardiovascolare, Disease, Special Article, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Physiology (medical), injury, Pandemic, Epidemiology, Medicine, AcademicSubjects/MED00200, Intensive care medicine, business.industry, Pathophysiology, Human medicine, Cardiology and Cardiovascular Medicine, business
Abstract

Aims Since its emergence in early 2020, the novel severe acute respiratory syndrome coronavirus 2 causing coronavirus disease 2019 (COVID-19) has reached pandemic levels, and there have been repeated outbreaks across the globe. The aim of this two-part series is to provide practical knowledge and guidance to aid clinicians in the diagnosis and management of cardiovascular disease (CVD) in association with COVID-19. Methods and results A narrative literature review of the available evidence has been performed, and the resulting information has been organized into two parts. The first, reported here, focuses on the epidemiology, pathophysiology, and diagnosis of cardiovascular (CV) conditions that may be manifest in patients with COVID-19. The second part, which will follow in a later edition of the journal, addresses the topics of care pathways, treatment, and follow-up of CV conditions in patients with COVID-19. Conclusion This comprehensive review is not a formal guideline but rather a document that provides a summary of current knowledge and guidance to practicing clinicians managing patients with CVD and COVID-19. The recommendations are mainly the result of observations and personal experience from healthcare providers. Therefore, the information provided here may be subject to change with increasing knowledge, evidence from prospective studies, and changes in the pandemic. Likewise, the guidance provided in the document should not interfere with recommendations provided by local and national healthcare authorities., Graphical Abstract Graphical Abstract

Published
2022

5. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice

Author

Visseren, F.L.J. Mach, F. Smulders, Y.M. Carballo, D. Koskinas, K.C. Back, M. Benetos, A. Biffi, A. Boavida, J.-M. Capodanno, D. Cosyns, B. Crawford, C. Davos, C.H. Desormais, I. Di Angelantonio, E. Franco, O.H. Halvorsen, S. Richard Hobbs, F.D. Hollander, M. Jankowska, E.A. Michal, M. Sacco, S. Sattar, N. Tokgozoglu, L. Tonstad, S. Tsioufis, K.P. Van Dis, I. Van Gelder, I.C. Wanner, C. Williams, B.

Published
2022

6. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice

Author

Visseren, F. L. J., Mach, F., Smulders, Y. M., Carballo, D., Koskinas, K. C., Back, M., Benetos, A., Biffi, A., Boavida, J. -M., Capodanno, D., Cosyns, B., Crawford, C., Davos, C. H., Desormais, I., DI Angelantonio, E., Franco, O. H., Halvorsen, S., Hobbs, F. D. R., Hollander, M., Jankowska, E. A., Michal, M., Sacco, S., Sattar, N., Tokgozoglu, L., Tonstad, S., Tsioufis, K. P., Van DIs, I., Van Gelder, I. C., Wanner, C., Williams, B., De Backer, G., Regitz-Zagrosek, V., Aamodt, A. H., Abdelhamid, M., Aboyans, V., Albus, C., Asteggiano, R., Borger, M. A., Brotons, C., Ielutkiene, J., Cifkova, R., Cikes, M., Cosentino, F., Dagres, N., De Backer, T., De Bacquer, D., Delgado, V., Den Ruijter, H., Dendale, P., Drexel, H., Falk, V., Fauchier, L., Ference, B. A., Ferrieres, J., Ferrini, M., Fisher, M., Fliser, D., Fras, Z., Gaita, D., Giampaoli, S., Gielen, S., Graham, I., Jennings, C., Jorgensen, T., Kautzky-Willer, A., Kavousi, M., Koenig, W., Konradi, A., Kotecha, D., Landmesser, U., Lettino, M., Lewis, B. S., Linhart, A., Lochen, M. -L., Makrilakis, K., Mancia, G., Marques-Vidal, P., Mcevoy, J. W., Mcgreavy, P., Merkely, B., Neubeck, L., Nielsen, J. C., Perk, J., Petersen, S. E., Petronio, A. S., Piepoli, M., Pogosova, N. G., Prescott, E. I. B., Ray, K. K., Reiner, Z., Richter, D. J., Ryden, L., Shlyakhto, E., Sitges, M., Sousa-Uva, M., Sudano, I., Tiberi, M., Touyz, R. M., Ungar, A., Verschuren, W. M. M., Wiklund, O., Wood, D., Zamorano, J. L., Crawford, C. A., Franco Duran, O. H., Richard Hobbs, F. D., Dis, I. V., Group, ESC Scientific Document, Clinical sciences, Cardio-vascular diseases, and Cardiology

Subjects
medicine.medical_specialty, Epidemiology, Population, air pollution, population, Guidelines, blood pressure, climate change, diabetes, healthy lifestyle, lifetime benefit, lifetime risk, lipids, nutrition, personalized, prevention, psychosocial factors, risk estimation, risk management, shared decision-making, smoking, stepwise approach, Risk Assessment, Humans, Primary Prevention, Risk Factors, Cardiovascular Diseases, Diabetes mellitus, medicine, Intensive care medicine, education, 610 Medicine & health, Risk management, education.field_of_study, business.industry, medicine.disease, Clinical Practice, Blood pressure, guidelines, Heart failure, Lifetime risk, Disease prevention, Cardiology and Cardiovascular Medicine, business, Stepwise approach, 360 Social problems & social services
Abstract

These are the clinical practice guidelines from the European Society of Cardiology on cardiovascular disease prevention in clinical practice, from 2021.

Published
2022

7. Novel drug-eluting stents in the treatment of de novo coronary lesions

Author

Tamburino C, Capodanno D, and Dipasqua F

Subjects
coronary stents, Diseases of the circulatory (Cardiovascular) system, RC666-701
Abstract

Davide Capodanno1,2, Fabio Dipasqua1, Corrado Tamburino1,21Department of Cardiology, Ferrarotto Hospital, University of Catania, Catania, Italy; 2ETNA Foundation, Catania, ItalyAbstract: Due to safety concerns in recent years, much effort has been devoted to improving the outcomes associated with drug-eluting stents (DESs). This review summarizes the current status of methodological and technical achievements reported in second-generation DES. Novel stents are described based on the component (the platform, the polymer, and the drug) that has undergone the most significant changes compared to earlier generation DES. An overview of the currently available evidence on the use of novel coronary devices in patients undergoing coronary revascularization is also reviewed.Keywords: coronary artery disease, stent, platform, polymer, drug, percutaneous coronary intervention, late lumen loss, follow-up, outcomes

Published
2011

8. European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1-epidemiology, pathophysiology, and diagnosis The Task Force for the management of COVID-19 of the European Society of Cardiology

Author

Baigent, C., Windecker, S., Andreini, D., Arbelo, E., Barbato, E., Bartorelli, A.L., Baumbach, A., Behr, E.R., Berti, S., Bueno, H., Capodanno, D., Cappato, R., Chieffo, A., Collet, J.P., Cuisset, T., Simone, G. de, Delgado, V., Dendale, P., Dudek, D., Edvardsen, T., Elvan, A., Gonzalez-Juanatey, J.R., Gori, M., Grobbee, D., Guzik, T.J., Halvorsen, S., Haude, M., Heidbuchel, H., Hindricks, G., Ibanez, B., Karam, N., Katus, H., Klok, F.A., Konstantinides, S.V., Landmesser, U., Leclercq, C., Leonardi, S., Lettino, M., Marenzi, G., Mauri, J., Metra, M., Morici, N., Mueller, C., Petronio, A.S., Polovina, M.M., Potpara, T., Praz, F., Prendergast, B., Prescott, E., Price, S., Pruszczyk, P., Rodriguez-Leor, O., Roffi, M., Romaguera, R., Rosenkranz, S., Sarkozy, A., Scherrenberg, M., Seferovic, P., Senni, M., Spera, F.R., Stefanini, G., Thiele, H., Tomasoni, D., Torracca, L., Touyz, R.M., Wilde, A.A., Williams, B., and European Soc Cardiology

Subjects
Myocarditis, Myocardial injury, Non-invasive imaging, ACE2, COVID-19, Arrhythmias, Cardiogenic shock, Biomarkers
Abstract

Aims Since its emergence in early 2020, the novel severe acute respiratory syndrome coronavirus 2 causing coronavirus disease 2019 (COVID-19) has reached pandemic levels, and there have been repeated outbreaks across the globe. The aim of this two-part series is to provide practical knowledge and guidance to aid clinicians in the diagnosis and management of cardiovascular disease (CVD) in association with COVID-19.Methods and results A narrative literature review of the available evidence has been performed, and the resulting information has been organized into two parts. The first, reported here, focuses on the epidemiology, pathophysiology, and diagnosis of cardiovascular (CV) conditions that may be manifest in patients with COVID-19. The second part, which will follow in a later edition of the journal, addresses the topics of care pathways, treatment, and follow-up of CV conditions in patients with COVID-19.Conclusion This comprehensive review is not a formal guideline but rather a document that provides a summary of current knowledge and guidance to practicing clinicians managing patients with CVD and COVID-19. The recommendations are mainly the result of observations and personal experience from healthcare providers. Therefore, the information provided here may be subject to change with increasing knowledge, evidence from prospective studies, and changes in the pandemic. Likewise, the guidance provided in the document should not interfere with recommendations provided by local and national healthcare authorities.[GRAPHICS].

Published
2021

9. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes

Author

Knuuti, Juhani, Wijns, William, Saraste, Antti, Capodanno, Davide, Barbato, Emanuele, Funck-Brentano, Christian, Prescott, Eva, Storey, Robert F, Deaton, Christi, Cuisset, Thomas, Agewall, Stefan, Dickstein, Kenneth, Edvardsen, Thor, Escaned, Javier, Gersh, Bernard J, Svitil, Pavel, Gilard, Martine, Hasdai, David, Hatala, Robert, Mahfoud, Felix, Masip, Josep, Muneretto, Claudio, Valgimigli, Marco, Achenbach, Stephan, Bax, Jeroen J, Neumann FJ, Sechtem U, Banning AP, Bonaros N, Bueno H, Bugiardini R, Chieffo A, Crea F, Czerny M, Delgado V, Dendale P, Flachskampf FA, Gohlke H, Grove EL, James S, Katritsis D, Landmesser U, Lettino M, Matter CM, Nathoe H, Niessner A, Patrono C, Petronio AS, Pettersen SE, Piccolo R, Piepoli MF, Popescu BA, Räber L, Richter DJ, Roffi M, Roithinger FX, Shlyakhto E, Sibbing D, Silber S, Simpson IA, Sousa-Uva M, Vardas P, Witkowski A, Zamorano JL, Achenbach S, Agewall S, Barbato E, Bax JJ, Capodanno D, Cuisset T, Deaton C, Dickstein K, Edvardsen T, Escaned J, Funck-Brentano C, Gersh BJ, Gilard M, Hasdai D, Hatala R, Mahfoud F, Masip J, Muneretto C, Prescott E, Saraste A, Storey RF, Svitil P, Valgimigli M, Windecker S, Aboyans V, Baigent C, Collet JP, Dean V, Fitzsimons D, Gale CP, Grobbee D, Halvorsen S, Hindricks G, Iung B, Jüni P, Katus HA, Leclercq C, Lewis BS, Merkely B, Mueller C, Petersen S, Touyz RM, Benkhedda S, Metzler B, Sujayeva V, Cosyns B, Kusljugic Z, Velchev V, Panayi G, Kala P, Haahr-Pedersen SA, Kabil H, Ainla T, Kaukonen T, Cayla G, Pagava Z, Woehrle J, Kanakakis J, Tóth K, Gudnason T, Peace A, Aronson D, Riccio C, Elezi S, Mirrakhimov E, Hansone S, Sarkis A, Babarskiene R, Beissel J, Maempel AJC, Revenco V, de Grooth GJ, Pejkov H, Juliebø V, Lipiec P, Santos J, Chioncel O, Duplyakov D, Bertelli L, Dikic AD, Studenčan M, Bunc M, Alfonso F, Bäck M, Zellweger M, Addad F, Yildirir A, Sirenko Y, Clapp B, Sorbonne Université (SU), Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Institute of cardiometabolism and nutrition (ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service de pharmacologie médicale [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre recherche en CardioVasculaire et Nutrition = Center for CardioVascular and Nutrition research (C2VN), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Département de Cardiologie [Hôpital de la Timone - APHM], Hôpital de la Timone [CHU - APHM] (TIMONE)-Assistance Publique - Hôpitaux de Marseille (APHM), Knuuti, Juhani, Wijns, William, Saraste, Antti, Capodanno, Davide, Barbato, Emanuele, Funck-Brentano, Christian, Prescott, Eva, Storey, Robert F, Deaton, Christi, Cuisset, Thoma, Agewall, Stefan, Dickstein, Kenneth, Edvardsen, Thor, Escaned, Javier, Gersh, Bernard J, Svitil, Pavel, Gilard, Martine, Hasdai, David, Hatala, Robert, Mahfoud, Felix, Masip, Josep, Muneretto, Claudio, Valgimigli, Marco, Achenbach, Stephan, Bax, Jeroen J, Neumann FJ, Sechtem U, Banning AP, Bonaros N, Bueno H, Bugiardini R, Chieffo A, Crea F, Czerny M, Delgado V, Dendale P, Flachskampf FA, Gohlke H, Grove EL, James S, Katritsis D, Landmesser U, Lettino M, Matter CM, Nathoe H, Niessner A, Patrono C, Petronio AS, Pettersen SE, Piccolo R, Piepoli MF, Popescu BA, Räber L, Richter DJ, Roffi M, Roithinger FX, Shlyakhto E, Sibbing D, Silber S, Simpson IA, Sousa-Uva M, Vardas P, Witkowski A, Zamorano JL, Achenbach S, Agewall S, Barbato E, Bax JJ, Capodanno D, Cuisset T, Deaton C, Dickstein K, Edvardsen T, Escaned J, Funck-Brentano C, Gersh BJ, Gilard M, Hasdai D, Hatala R, Mahfoud F, Masip J, Muneretto C, Prescott E, Saraste A, Storey RF, Svitil P, Valgimigli M, Windecker S, Aboyans V, Baigent C, Collet JP, Dean V, Delgado V, Fitzsimons D, Gale CP, Grobbee D, Halvorsen S, Hindricks G, Iung B, Jüni P, Katus HA, Landmesser U, Leclercq C, Lettino M, Lewis BS, Merkely B, Mueller C, Petersen S, Petronio AS, Richter DJ, Roffi M, Shlyakhto E, Simpson IA, Sousa-Uva M, Touyz RM, Benkhedda S, Metzler B, Sujayeva V, Cosyns B, Kusljugic Z, Velchev V, Panayi G, Kala P, Haahr-Pedersen SA, Kabil H, Ainla T, Kaukonen T, Cayla G, Pagava Z, Woehrle J, Kanakakis J, Tóth K, Gudnason T, Peace A, Aronson D, Riccio C, Elezi S, Mirrakhimov E, Hansone S, Sarkis A, Babarskiene R, Beissel J, Maempel AJC, Revenco V, de Grooth GJ, Pejkov H, Juliebø V, Lipiec P, Santos J, Chioncel O, Duplyakov D, Bertelli L, Dikic AD, Studenčan M, Bunc M, Alfonso F, Bäck M, Zellweger M, Addad F, Yildirir A, Sirenko Y, Clapp B, Clinical sciences, Cardio-vascular diseases, Cardiology, Knuuti, Juhani [0000-0003-3156-9593], Apollo - University of Cambridge Repository, Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases (ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Institut de Cardiométabolisme et Nutrition = Institute of Cardiometabolism and Nutrition [CHU Pitié Salpêtrière] (IHU ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE), University of Zurich, Knuuti, J., Wijns, W., Achenbach, S., Agewall, S., Barbato, E., Bax, J. J., Capodanno, D., Cuisset, T., Deaton, C., Dickstein, K., Edvardsen, T., Escaned, J., Funck-Brentano, C., Gersh, B. J., Gilard, M., Hasdai, D., Hatala, R., Mahfoud, F., Masip, J., Muneretto, C., Prescott, E., Saraste, A., Storey, R. F., Svitil, P., Valgimigli, M., Windecker, S., Aboyans, V., Baigent, C., Collet, J. -P., Dean, V., Delgado, V., Fitzsimons, D., Gale, C. P., Grobbee, D. E., Halvorsen, S., Hindricks, G., Iung, B., Juni, P., Katus, H. A., Landmesser, U., Leclercq, C., Lettino, M., Lewis, B. S., Merkely, B., Mueller, C., Petersen, S., Petronio, A. S., Richter, D. J., Roffi, M., Shlyakhto, E., Simpson, I. A., Sousa-Uva, M., Touyz, R. M., Benkhedda, S., Metzler, B., Sujayeva, V., Cosyns, B., Kusljugic, Z., Velchev, V., Panayi, G., Kala, P., Haahr-Pedersen, S. A., Kabil, H., Ainla, T., Kaukonen, T., Cayla, G., Pagava, Z., Woehrle, J., Kanakakis, J., Toth, K., Gudnason, T., Peace, A., Aronson, D., Riccio, C., Elezi, S., Mirrakhimov, E., Hansone, S., Sarkis, A., Babarskiene, R., Beissel, J., Cassar Maempel, A. J., Revenco, V., de Grooth, G. J., Pejkov, H., Juliebo, V., Lipiec, P., Santos, J., Chioncel, O., Duplyakov, D., Bertelli, L., Dikic, A. D., Studencan, M., Bunc, M., Alfonso, F., Back, M., Zellweger, M., Addad, F., Yildirir, A., Sirenko, Y., and Clapp, B.

Subjects
anti-ischaemic drug, chronic coronary syndromes, medicine.medical_treatment, [SDV]Life Sciences [q-bio], lipid-lowering drugs, Diagnostic Techniques, Cardiovascular, antithrombotic therapy, Disease, 030204 cardiovascular system & hematology, Guideline, Coronary artery disease, 0302 clinical medicine, Disease management (health), Societies, Medical, ComputingMilieux_MISCELLANEOUS, chronic coronary syndrome, angina pectori, Disease Management, food and beverages, imaging, risk assessment, Syndrome, 3. Good health, Natural history, Europe, Cardiology, Cardiology and Cardiovascular Medicine, coronary artery disease, medicine.medical_specialty, lifestyle modifications, anti-ischaemic drugs, Ischemia, 610 Medicine & health, vasospastic angina, Guidelines, Revascularization, diagnostic testing, 11171 Cardiocentro Ticino, 2705 Cardiology and Cardiovascular Medicine, 03 medical and health sciences, angina pectoris, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Internal medicine, medicine, Journal Article, Humans, business.industry, screening, fungi, 030229 sport sciences, medicine.disease, lipid-lowering drug, Angina pectoris, Anti-ischaemic drugs, Antithrombotic therapy, Chronic coronary syndromes, Diagnostic testing, Imaging, Lifestyle modifications, Lipid-lowering drugs, Microvascular angina, Myocardial ischaemia, Myocardial revascularization, Risk assessment, Screening, Vasospastic angina, myocardial ischaemia, myocardial revascularization, Heart failure, microvascular angina, Chronic Disease, Settore MED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLARE, lifestyle modification, Coronary Artery Disease/diagnosis, business, Fibrinolytic agent
Abstract

Coronary artery disease (CAD) is a pathological process characterized by atherosclerotic plaque accumulation in the epicardial arteries, whether obstructive or non-obstructive. This process can be modified by lifestyle adjustments, pharmacological therapies, and invasive interventions designed to achieve disease stabilization or regression. The disease can have long, stable periods but can also become unstable at any time, typically due to an acute atherothrombotic event caused by plaque rupture or erosion. However, the disease is chronic, most often progressive, and hence serious, even in clinically apparently silent periods. The dynamic nature of the CAD process results in various clinical presentations, which can be conveniently categorized as either acute coronary syndromes (ACS) or chronic coronary syndromes (CCS). The Guidelines presented here refer to the management of patients with CCS. The natural history of CCS is illustrated in Figure 1.

Published
2019

11. 2019 ESC Guide on the Diagnosis and Treatment of Chronic Coronary Syndromes

Author

Knuuti, J., Wijns, W., Saraste, A., Capodanno, D., Barbato, E., Funck-Brentano, C., Prescott, E., Storey, R.F., Deaton, C., Cuisset, T., Agewall, S., Dickstein, K., Edvardsen, T., Escaned, J., Gersh, B.J., Svitil, P., Gilard, M., Hasdai, D., Hatala, R., Mahfoud, F., Masip, J., Muneretto, C., Valgimigli, M., Achenbach, S., Bax, J.J., and Soc Europea Cardiologia ESC Diagno

Published
2020

12. The SYNTAX score on its way out or ... towards artificial intelligence: part

Author

Serruys, P.W., Chichareon, P., Modolo, R., Leaman, D.M., Reiber, J.H.C., Emanuelsson, H., Mario, C. di, Pijls, N.H.J., Morel, M.A., Valgimigli, M., Farooq, V., Klaveren, D. van, Capodanno, D., Andreini, D., Bourantas, C.V., Davies, J., Banning, A.P., Escaned, J., Piek, J.J., Echavarria-Pinto, M., Taylor, C.A., Thomsen, B., Collet, C., Pompilio, G., Bartorelli, A.L., Glocker, B., Dressler, O., Stone, G.W., and Onuma, Y.

Published
2020

13. Derivation, Validation, and Prognostic Utility of a Prediction Rule for Nonresponse to Clopidogrel: The ABCD-GENE Score

Author

Angiolillo, D. J., Capodanno, D., Danchin, N., Simon, T., Bergmeijer, T. O., ten Berg, J. M., Sibbing, D., and Price, M. J.

Subjects
Male, Time Factors, Databases, Factual, Pharmacogenomic Variants, Myocardial Infarction, Drug Resistance, outcomes, Risk Assessment, genetic testing, Body Mass Index, Databases, Percutaneous Coronary Intervention, Predictive Value of Tests, Risk Factors, Clinical Decision Rules, Diabetes Mellitus, Humans, Obesity, Renal Insufficiency, Renal Insufficiency, Chronic, Chronic, Factual, Aged, Randomized Controlled Trials as Topic, clopidogrel, Coronary Thrombosis, Age Factors, Reproducibility of Results, Middle Aged, Cytochrome P-450 CYP2C19, Treatment Outcome, Purinergic P2Y Receptor Antagonists, Female, Platelet Aggregation Inhibitors
Published
2020

16. Aspirin Desensitization in Patients with Coronary Artery Disease

Author

Rossini R, Iorio A, Pozzi R, Bianco M, Musumeci G, Leonardi S, Lettieri C, Bossi I, Colombo P, Rigattieri S, Dossena C, Anzuini A, Capodanno D, Senni M, Angiolillo DJ, Rossini, R, Iorio, A, Pozzi, R, Bianco, M, Musumeci, G, Leonardi, S, Lettieri, C, Bossi, I, Colombo, P, Rigattieri, S, Dossena, C, Anzuini, A, Capodanno, D, Senni, M, and Angiolillo, D

Subjects
aspirin, percutaneous coronary intervention, hypersensitivity, coronary artery disease, acute coronary syndrome
Abstract

Background - There are limited data on aspirin (ASA) desensitization for patients with coronary artery disease. The aim of the present study was to assess the safety and efficacy of a standard rapid desensitization protocol in patients with ASA sensitivity undergoing coronary angiography. Methods and Results - This is a prospective, multicenter, observational study including 7 Italian centers including patients with a history of ASA sensitivity undergoing coronary angiography with intent to undergo percutaneous coronary intervention. A total of 330 patients with history of ASA sensitivity with known/suspected stable coronary artery disease or presenting with an acute coronary syndrome, including ST-segment-elevation myocardial infarction were enrolled. Adverse effects to aspirin included urticaria (n=177, 53.6%), angioedema (n=69, 20.9%), asthma (n=65, 19.7%), and anaphylactic reaction (n=19, 5.8%). Among patients with urticaria/angioedema, 13 patients (3.9%) had a history of idiopathic chronic urticaria. All patients underwent a rapid ASA (5.5 hours) desensitization procedure. The desensitization procedure was performed before cardiac catheterization in all patients, except for those (n=78, 23.6%) presenting with ST-segment-elevation myocardial infarction who underwent the desensitization after primary percutaneous coronary intervention. Percutaneous coronary intervention was performed in 235 patients (71%) of the overall study population. The desensitization procedure was successful in 315 patients (95.4%) and in all patients with a history of anaphylactic reaction. Among the 15 patients (4.6%) who did not successfully respond to the desensitization protocol, adverse reactions were minor and responded to treatment with corticosteroids and antihistamines. Among patients with successful in-hospital ASA desensitization, 253 patients (80.3%) continued ASA for at least 12 months. Discontinuation of ASA in the 62 patients (19.7%) who had responded to the desensitization protocol was because of medical decision and not because of hypersensitivity reactions. Conclusions - A standard rapid desensitization protocol is safe and effective across a broad spectrum of patients, irrespective of the type of aspirin sensitivity manifestation, with indications to undergo coronary angiography with intent to perform percutaneous coronary intervention. Clinical Trial Registration - URL: http://www.clinicaltrials.gov. Unique identifier: NCT02848339.

Published
2017

17. Early P2Y12 Inhibitors Escalation in Primary PCI Patients: Insights from the RENOVAMI Registry

Author

Lupi, A. Bona, R.D. Meliga, E. Capodanno, D. Schaffer, A. Bongo, A.S. Gaudio, G. Guasti, L. Alexopoulos, D. Valgimigli, M. Porto, I.

Subjects
cardiovascular diseases
Abstract

Background Early escalation from clopidogrel to new generation P2Y12 inhibitors is common practice in patients with ST-elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (pPCI). Real-world data about this strategy, however, are limited. Methods From 2012 to 2015, 1,057 consecutive STEMI patients treated with pPCI in an Italian hub-and-spoke network were prospectively included in an observational registry (RENOVAMI, ClinicalTrials.gov Identifier: NCT01760382). We compared the prevalence, predictive factors and in-hospital outcomes of patients escalated to a new generation P2Y12 inhibitor within the first 24 hours from pPCI with those continuing on admission antiplatelet therapy. Results In the first 24 hours after pPCI, 165 patients (15.6%) were escalated from clopidogrel to a new generation P2Y12 inhibitor, while de-escalation to clopidogrel was occasional (19 patients, 1.8%) and switch between new generation P2Y12 inhibitors was rare (8 patients, 0.8%, all from ticagrelor to prasugrel). Drug eluting stent use (adjusted odds ratio [OR], 2.19, 95% confidence interval [CI], 1.55-3.08, p = 0.0002) and impaired renal function (adjusted OR, 0.19, 95% CI, 0.05-0.77, p = 0.02) were the only independent predictive factors for the decision to escalate. After adjustment for potential confounders, escalation did not predict in-hospital outcomes, whereas the overall use of new generation P2Y12 inhibitors was correlated with a better in-hospital survival (adjusted hazard ratio, 0.47, 95% CI, 0.25-0.91, p = 0.03). Moreover, escalation did not influence bleeding rates. Conclusions In this prospective registry of STEMI patients treated with pPCI and contemporary antiplatelet therapy, early escalation to a new generation P2Y12 inhibitor appeared safe and did not significantly affect in-hospital bleeding rates. © 2018 Schattauer.

Published
2018

18. Transcatheter or surgical treatment of severe aortic stenosis and coronary artery disease:a comparative analysis from the Italian OBSERVANT study

Author

Barbanti, M. (Marco), Buccheri, S. (Sergio), Capodanno, D. (Davide), D'Errigo, P. (Paola), Ranucci, M. (Marco), Rosato, S. (Stefano), Santoro, G. (Gennaro), Fusco, D. (Danilo), Tamburino, C. (Corrado), Biancari, F. (Fausto), Seccareccia, F. (Fulvia), and O. R. (OBSERVANT Research Group)

Subjects
TAVI, aortic stenosis, PCI, cardiovascular diseases, SAVR, CABG, coronary artery disease
Abstract

Background: To assess clinical outcomes of patients with concomitant severe aortic stenosis (AS) and coronary artery disease (CAD) who underwent transcatheter aortic valve implantation (TAVI) and percutaneous coronary intervention (PCI) or surgical aortic valve replacement (SAVR) and coronary artery bypass grafting (CABG). Methods: Data were extracted from the multicenter OBSERVANT study. For the purposes of the present analysis, we included only patients with established stable CAD meeting any of the following inclusion criteria: 1) TAVI patients with CAD undergoing staged PCI or TAVI and PCI in the same session; 2) SAVR patients undergoing combined SAVR and CABG in the same session. Results: After propensity-score matching, a total of 472 patients (236 per group) were identified. Among TAVI patients, PCI was performed prior to the procedure in 217 patients (92.0%), whereas concomitant TAVI and PCI were performed in 19 patients (8.0%). At 3-year, there was no difference in survival between the two groups (KM estimate of freedom from death for SAVR and TAVI patients of 0.742 and 0.650, respectively; log-rank p-value of 0.105). The rate of MACCE was comparable between the two groups (KM estimate of freedom from MACCE for SAVR and TAVI patients of 0.683 and 0.582, respectively; log-rank p-value of 0.115). Conclusions: In patients with associated severe AS and CAD, percutaneous treatment (TAVR and staged or concomitant PCI) was comparable to surgical treatment (SAVR and concomitant CABG) with respect to the early and mid-term risk of death from any cause, myocardial infarction, stroke and unplanned revascularization.

Published
2018

19. Is the Metallic Stent a Safe Treatment for Bioresorbable Scaffold Failure? Insights from Optical Coherence Tomography

Author

Capranzano P., Francaviglia B., Capodanno D., Buccheri S., Tamburino C. I., Gargiulo G., Tamburino C., Capranzano, P., Francaviglia, B., Capodanno, D., Buccheri, S., Tamburino, C. I., Gargiulo, G., and Tamburino, C.

Subjects
metal-in-polymer, bioresorbable scaffold, Prosthesis Design, struts apposition, failure, Everolimu, evagination, Treatment Outcome, Tissue Scaffold, fracture, Absorbable Implant, Stent, Drug-Eluting Stent, positive remodeling, Tomography, Optical Coherence, Human
Published
2016

20. Computing Methods for Composite Clinical Endpoints in Unprotected Left Main Coronary Artery Revascularization: A Post Hoc Analysis of the DELTA Registry

Author

Capodanno D., Gargiulo G., Buccheri S., Chieffo A., Meliga E., Latib A., Park S. -J., Onuma Y., Capranzano P., Valgimigli M., Narbute I., Makkar R. R., Palacios I. F., Kim Y. -H., Buszman P. E., Chakravarty T., Sheiban I., Mehran R., Naber C., Margey R., Agnihotri A., Marra S., Leon M. B., Moses J. W., Fajadet J., Lefevre T., Morice M. -C., Erglis A., Alfieri O., Serruys P. W., Colombo A., Tamburino C., Capodanno, Davide, Gargiulo, Giuseppe, Buccheri, Sergio, Chieffo, Alaide, Meliga, Emanuele, Latib, Azeem, Park, Seung Jung, Onuma, Yoshinobu, Capranzano, Piera, Valgimigli, Marco, Narbute, Inga, Makkar, Raj R., Palacios, Igor F., Kim, Young Hak, Buszman, Pawel E., Chakravarty, Tarun, Sheiban, Imad, Mehran, Roxana, Naber, Christoph, Margey, Ronan, Agnihotri, Arvind, Marra, Sebastiano, Leon, Martin B., Moses, Jeffrey W., Fajadet, Jean, Lefã¨vre, Thierry, Morice, Marie Claude, Erglis, Andrej, Alfieri, Ottavio, Serruys, Patrick W., Colombo, Antonio, Tamburino, Corrado, Cardiology, Capodanno, D., Gargiulo, G., Buccheri, S., Chieffo, A., Meliga, E., Latib, A., Park, S. -J., Onuma, Y., Capranzano, P., Valgimigli, M., Narbute, I., Makkar, R. R., Palacios, I. F., Kim, Y. -H., Buszman, P. E., Chakravarty, T., Sheiban, I., Mehran, R., Naber, C., Margey, R., Agnihotri, A., Marra, S., Leon, M. B., Moses, J. W., Fajadet, J., Lefevre, T., Morice, M. -C., Erglis, A., Alfieri, O., Serruys, P. W., Colombo, A., and Tamburino, C.

Subjects
Registrie, Male, Data Interpretation, Time Factors, Logistic Model, Time Factor, Endpoint Determination, left main, win ratio, Myocardial Infarction, Coronary Artery Disease, Kaplan-Meier Estimate, competing risk, Risk Assessment, Percutaneous Coronary Intervention, Risk Factors, Models, Drug-Eluting Stent, Humans, Registries, Coronary Artery Bypass, Propensity Score, Multivariate Analysi, Aged, Proportional Hazards Models, Andersen-Gill, Models, Statistical, Coronary Artery Bypa, Risk Factor, Drug-Eluting Stents, Markov Chain, Statistical, Middle Aged, weighted composite event(s), Cerebrovascular Disorders, Data Interpretation, Statistical, Female, Logistic Models, Markov Chains, Multivariate Analysis, Research Design, Treatment Outcome, Cardiology and Cardiovascular Medicine, Cerebrovascular Disorder, Proportional Hazards Model, Human
Abstract

Objectives The study sought to investigate the impact of different computing methods for composite endpoints other than time-to-event (TTE) statistics in a large, multicenter registry of unprotected left main coronary artery (ULMCA) disease. Background TTE statistics for composite outcome measures used in ULMCA studies consider only the first event, and all the contributory outcomes are handled as if of equal importance. Methods The TTE, Andersen-Gill, win ratio (WR), competing risk, and weighted composite endpoint (WCE) computing methods were applied to ULMCA patients revascularized by percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) at 14 international centers. Results At a median follow-up of 1,295 days (interquartile range: 928 to 1,713 days), all analyses showed no difference in combinations of death, myocardial infarction, and cerebrovascular accident between PCI and CABG. When target vessel revascularization was incorporated in the composite endpoint, the TTE (p = 0.03), Andersen-Gill (p = 0.04), WR (p = 0.025), and competing risk (p < 0.001) computing methods showed CABG to be significantly superior to PCI in the analysis of 1,204 propensity-matched patients, whereas incorporating the clinical relevance of the component endpoints using WCE resulted in marked attenuation of the treatment effect of CABG, with loss of significance for the difference between revascularization strategies (p = 0.10). Conclusions In a large study of ULMCA revascularization, incorporating the clinical relevance of the individual outcomes resulted in sensibly different findings as compared with the conventional TTE approach. In particular, using the WCE computing method, PCI and CABG were no longer significantly different with respect to the composite of death, myocardial infarction, cerebrovascular accident, or target vessel revascularization at a median of 3 years.

Published
2016

21. Quantitative angiography methods for bifurcation lesions: a consensus statement update from the European Bifurcation Club

Author

Collet, C., Onuma, Y., Cavalcante, R., Grundeken, M., Genereux, P., Popma, J., Costa, R., Stankovic, G., Tu, S., Reiber, J.H.C., Aben, J.P., Lassen, J.F., Louvard, Y., Lansky, A., Serruys, P.W., Byrne, R.A., Capodanno, D., Waksman, R., Garcia-Garcia, H.M., Arbab-Zadeh, A., EAPCI Sci Documents Comm, EAPCI, ACS - Heart failure & arrhythmias, Graduate School, ACS - Amsterdam Cardiovascular Sciences, and Cardiology

Subjects
Coronary angiography, medicine.medical_specialty, Consensus, Coronary Artery Disease, 030204 cardiovascular system & hematology, Coronary Angiography, Severity of Illness Index, Radiographic image interpretation, 03 medical and health sciences, 0302 clinical medicine, Medicine, Humans, Medical physics, 030212 general & internal medicine, Bifurcation lesion, Bifurcation, Statement (computer science), business.industry, Quantitative angiography, Coronary Stenosis, Vessel diameter, Bifurcation analysis, bifurcation, quantitative coronary angiography (QCA), Radiographic Image Interpretation, Computer-Assisted, Other imaging modalities, Cardiology and Cardiovascular Medicine, business, Software
Abstract

Bifurcation lesions represent one of the most challenging lesion subsets in interventional cardiology. The European Bifurcation Club (EBC) is an academic consortium whose goal has been to assess and recommend the appropriate strategies to manage bifurcation lesions. The quantitative coronary angiography (QCA) methods for the evaluation of bifurcation lesions have been subject to extensive research. Single-vessel QCA has been shown to be inaccurate for the assessment of bifurcation lesion dimensions. For this reason, dedicated bifurcation software has been developed and validated. These software packages apply the principles of fractal geometry to address the "step-down" in the bifurcation and to estimate vessel diameter accurately. This consensus update provides recommendations on the QCA analysis and reporting of bifurcation lesions based on the most recent scientific evidence from in vitro and in vivo studies and delineates future advances in the field of QCA dedicated bifurcation analysis.

Published
2017

22. Impact of postoperative acute kidney injury on clinical outcomes after TAVI: A meta-analysis of 5,971 patients

Author

Gargiulo G, Sannino A, Capodanno D, Perrino C, Capranzano P, Barbanti M, Stabile E, Trimarco B, Tamburino C, Esposito G., Gargiulo, G, Sannino, A, Capodanno, D, Perrino, C, Capranzano, P, Barbanti, M, Stabile, E, Trimarco, B, Tamburino, C, and Esposito, G.

Subjects
acute kidney injury, prognosis, severe aortic stenosis, transcatheter aortic valve implantation
Abstract

Background There is conflicting evidence on the safety and efficacy of transcatheter aortic valve implantation (TAVI) in patients with postoperative acute kidney injury (AKI). Therefore, we conducted a meta-analysis on the impact of AKI on clinical outcomes after TAVI. Methods and Results Twenty-four studies including 5,971 patients were analyzed. The mean incidence of AKI in this population was 22.1% ± 11.2. Postoperative AKI significantly increased early (odds ratio [OR] 5.09; 95% confidence interval [CI], 4.03-6.43 and OR 6.14; 95% CI, 3.26-11.55) and 1-year (OR 3.27; 95% CI, 2.42-4.42 and OR 1.93; 95% CI, 1.38-2.71) all-cause and cardiovascular mortality respectively, but also early myocardial infarction (OR 3.30; 95% CI, 1.44-7.57), life-threatening bleeding (OR 2.90; 95% CI, 1.67-5.05), need for transfusion (OR 2.42; 95% CI, 1.96-2.99), and dialysis (OR 14.35; 95% CI, 6.21-33.20), with a non-significant increase of stroke (OR 1.66; 95% CI, 0.94-2.95), hospitalization (mean difference [MD] 1.73; 95% CI, -0.31 to 3.77) and contrast medium received (MD 4.74; 95% CI, -2.33 to 11.81). Conclusions Postoperative AKI seems to significantly worsen TAVI prognosis. The results of the present meta-analysis should be considered hypothesis-generating and future studies on risk stratification, prevention, and postoperative management are needed.

Published
2015

23. Long term clinical outcomes after percutaneous coronary intervention vs coronary artery bypass grafting for ostial/midshaft lesions in unprotected left main coronary artery from the DELTA registry. A multicenter registry evaluating percutaneous coronary intervention vs coronary artery bypass grafting for left main treatment

Author

Naganuma T, Chieffo A, Meliga E, Capodanno D, Park SJ, Onuma Y, Valgimigli M, Jegere S, Makkar RR, Palacios IF, Costopoulos C, Kin YH, Buszman PP, Chakravarty T, Sheiban I, Mehran R, Naber C, Margey R, Agnihotri A, Marra S, Capranzano P, Leon MB, Moses JW, Fajadet J, Lefevre T, Morice MC, Erglis A, Tamburino C, ALFIERI, OTTAVIO, Serruys PW, COLOMBO , ANTONIO, Naganuma, T, Chieffo, A, Meliga, E, Capodanno, D, Park, Sj, Onuma, Y, Valgimigli, M, Jegere, S, Makkar, Rr, Palacios, If, Costopoulos, C, Kin, Yh, Buszman, Pp, Chakravarty, T, Sheiban, I, Mehran, R, Naber, C, Margey, R, Agnihotri, A, Marra, S, Capranzano, P, Leon, Mb, Moses, Jw, Fajadet, J, Lefevre, T, Morice, Mc, Erglis, A, Tamburino, C, Alfieri, Ottavio, Serruys, Pw, and Colombo, Antonio

Published
2014

24. Mini-Crush Versus T-Provisional Techniques in Bifurcation Lesions. Clinical and Angiographic Long-Term Outcome After Implantation of Drug-Eluting Stents

Author

Galassi A. R., Tomasello S. D., Capodanno D., Barrano G., Ussia G. P., Tamburino C., Galassi A.R., Tomasello S.D., Capodanno D., Barrano G., Ussia G.P., and Tamburino C.

Subjects
bifurcation lesion, T-provisional, stent, mini-crush, DES
Abstract

Objectives: This retrospective study sought to assess the clinical and angiographic long-term outcome after implanting drug-eluting stents in bifurcation lesions with the T-provisional (T-prov) technique and mini-crush (MC) technique. Background: The best option on the treatment of coronary bifurcation lesions is a subject of considerable debate. However, recent evidence suggests that bifurcation lesions might be treated by drug-eluting stent on both branches using the MC technique with a low rate of major adverse cardiac event and restenosis. Methods: From April 2004 to July 2006, 457 patients were consecutively treated with either MC technique (n = 199) or T-prov technique (n = 258). Of these latter, 170 patients were treated with 1 stent and 88 patients with 2 stents. The 9-month angiographic follow-up was completed in 188 of 229 (82.1%) bifurcation lesions of MC patients and in 207 of 266 lesions (77.8%) of T-prov patients. Results: After a propensity score adjustment, 2-year cumulative major adverse cardiac events were similar between groups (p = 0.16). The MC group compared with the T-prov 1-stent group had significantly lower main and side branches restenosis (hazard ratio [HR]: 0.52, 95% confidence interval [CI]: 0.27 to 0.99; p = 0.047; and HR: 0.41, 95% CI: 0.20 to 0.85; p = 0.016, respectively). However, the MC group compared with the T-prov-only group had significantly lower side branch restenosis (HR: 0.55, 95% CI: 0.37 to 0.82; p = 0.004). Conclusions: Both techniques of bifurcation treatment met high procedural success with low complication rates and similar major adverse cardiac event long-term outcome. However, the MC technique yields a lower restenosis rate at both main and side branches. These results may confirm the advantage of using prescheduled 2-stent technique to give a complete coverage of the side branches' ostium. © 2009 American College of Cardiology Foundation.

Published
2009

28. Early and long-term outlook of percutaneous coronary intervention for bifurcation lesions in young patients

Author

Gaspardone, A, Roversi, S, Sangiorgi, G, Biondi Zoccai, G, Romagnoli, E, Sheiban, I, De Servi, S, Tamburino, C, Colombo, A, Burzotta, F, Presbitero, P, Bolognese, L, Paloscia, L, Rubino, P, Sardella, G, Briguori, C, Niccoli, L, Franco, G, Di Girolamo, D, Piatti, L, Greco, C, Petronio, S, Loi, B, Lioy, E, Benassi, A, Patti, A, Capodanno, D, and Modena, M

Subjects
Adult, Male, medicine.medical_specialty, Time Factors, medicine.medical_treatment, Settore MED/11 - Malattie dell'Apparato Cardiovascolare, Coronary artery disease, Lesion, Percutaneous Coronary Intervention, Age, Internal medicine, Stent, Medicine, Humans, cardiovascular diseases, Myocardial infarction, Percutaneous transluminal coronary angioplasty, Aged, Retrospective Studies, business.industry, percutaneous coronary intervention, Age Factors, Percutaneous coronary intervention, Retrospective cohort study, Middle Aged, medicine.disease, Treatment Outcome, Conventional PCI, Cardiology, Female, Bifurcation, medicine.symptom, Cardiology and Cardiovascular Medicine, business, Coronary Artery Disease, coronary artery disease, age, stent, percutaneous transluminal coronary angioplasty, bifurcation, Mace
Abstract

Coronary artery disease is most common in older patients, but may occur in younger subjects. The outlook of young patients after percutaneous coronary intervention (PCI) of challenging lesion subsets such as coronary bifurcations, is not established. We thus aimed to appraise the early and long-term results of PCI for bifurcations in young patients.A multicenter, retrospective study was conducted enrolling consecutive patients undergoing bifurcation PCI between 2002 and 2006 in 22 Italian centers. Patients were divided in 2 groups: age ≤ 45 years, and age45 years. The primary end-point was long-term rate of major adverse cardiac events (MACE).4,314 patients were included: 195 (4.5%) in the younger group, and 4119 (95.5%) in the older group. 30-day outcomes did not show significant differences in MACE rates, with 1.0% in the ≤ 45 years group and 2.1% in the45 years group (p=0.439), with death in 0.5% and 1.2% (p=0.388). At long-term follow-up (24.4 ± 15.1 months), younger patients showed similar rates of MACE, (12.8% vs. 16.6%, p=0.161), myocardial infarction (3.1% vs. 3.7%, p=0.633), target lesion revascularization (11.3% vs. 12.5%, p=0.627), or stent thrombosis (1.5% vs. 2.8%, p=0.294), despite an increased risk of death in older patients (1.0% vs. 5.0%, p=0.012). Even at extensive multivariable analysis, younger patients still faced a similar risk of MACE (HR=0.78 [0.48-1.27], p=0.318).Despite their low age, young patients undergoing PCI for bifurcation face a significant risk of early and late non-fatal adverse events. Thus, they should not be denied careful medical management and follow-up.

Published
2012

29. Is intravascular ultrasound beneficial for percutaneous coronary intervention of bifurcation lesions? Evidence from a 4,314-patient registry

Author

Biondi Zoccai, G, Sangiorgi, G, Sheiban, I, Romagnoli, E, De Servi, S, Tamburino, C, Colombo, A, Burzotta, F, Presbitero, P, Bolognese, L, Paloscia, L, Rubino, P, Sardella, G, Briguori, C, Niccoli, L, Franco, G, Di Girolamo, D, Piatti, L, Greco, C, and Capodanno, D

Subjects
Male, Time Factors, medicine.medical_treatment, Coronary, Myocardial Infarction, Settore MED/11 - Malattie dell'Apparato Cardiovascolare, Coronary Artery Disease, Coronary artery disease, Risk Factors, Intravascular ultrasound, Myocardial infarction, Registries, Angioplasty, Balloon, Coronary, Ultrasonography, medicine.diagnostic_test, Interventional, percutaneous transluminal coronary angioplasty, Drug-Eluting Stents, General Medicine, Middle Aged, surgical procedures, operative, Treatment Outcome, Italy, Cardiology, Female, bifurcation, coronary artery disease, intravascular ultrasound, stent, Radiology, Cardiology and Cardiovascular Medicine, medicine.medical_specialty, Risk Assessment, Internal medicine, Angioplasty, medicine, Humans, cardiovascular diseases, Ultrasonography, Interventional, Retrospective Studies, Aged, Proportional Hazards Models, Chi-Square Distribution, business.industry, Stent, Percutaneous coronary intervention, Thrombosis, medicine.disease, Conventional PCI, business, Mace, Balloon
Abstract

Coronary bifurcations remain a challenging lesion subset for percutaneous coronary intervention (PCI). It is unclear whether intravascular ultrasound (IVUS) guidance can improve PCI results in bifurcations. We aimed to compare IVUS-guided PCI versus standard PCI in a large registry of patients undergoing PCI for bifurcations in the drug-eluting stent era. A multicenter, retrospective study was conducted enrolling consecutive patients undergoing bifurcation PCI between January 2002 and December 2006 at 22 centers. The primary end-point was the long term rate of major adverse cardiac events [MACE, i.e. death, myocardial infarction or target lesion revascularization (TLR)]. A total of 4,314 patients were included, 226 (5.2%) undergoing IVUS-guided PCI, and 4,088 (94.8%) standard PCI. Early (30-day) outcomes were similar in the two groups, with MACE in 1.3 versus 2.1%, respectively, death in 0.9 versus 1.0%, and stent thrombosis in 0 versus 0.6% (all p > 0.05). After 24 ± 15 months, unadjusted rates of MACE were 17.7 versus 16.4%, with death in 2.7 versus 4.9%, myocardial infarction in 4.4 versus 3.7%, TLR in 15.0 versus 12.3%, and stent thrombosis in 3.1 versus 2.7% (all p > 0.05). Even at multivariable Cox proportional hazard analysis with propensity score adjustment, IVUS was not associated with any statistically significant impact on the risk of MACE, death, myocardial infarction, TLR (neither on the main branch nor on the side branch), or stent thrombosis (all p > 0.05). Despite a sound rationale to choose stent size, optimize stent expansion and guide kissing inflation, IVUS usage during PCI for coronary bifurcation lesions was not associated with significant clinical benefits in this large retrospective study.

Published
2011

32. Real-world outcome of coronary bifurcation lesions in the drug-eluting stent era: results from the 4,314-patient Italian Society of Invasive Cardiology (SICI-GISE) Italian Multicenter Registry on Bifurcations (I-BIGIS)

Author

Romagnoli, E., Servi, S. D., Tamburino, C., Colombo, A., Burzotta, F., Presbitero, P., Bolognese, L., Paloscia, L., Rubino, P., Sardella, G., Briguori, C., Ettori, F., Franco, G., Girolamo, D. D., Sheiban, Imad, Piatti, L., Greco, C., Petronio, S., Loi, B., Lioy, E., Benassi, A., Patti, A., Gaspardone, A., Capodanno, D., Biondi Zoccai, G. G. L., Sangiorgi, G., and Study Group Milan, I. I.

Subjects
Male, medicine.medical_specialty, medicine.medical_treatment, Coronary, Disease, Coronary Artery Disease, Lesion, medicine, Clinical endpoint, Humans, cardiovascular diseases, Myocardial infarction, Registries, Angioplasty, Balloon, Coronary, Aged, Angioplasty, Balloon, Coronary Stenosis, Drug-Eluting Stents, Female, Italy, Middle Aged, Research Design, Thrombosis, Treatment Outcome, business.industry, Percutaneous coronary intervention, medicine.disease, Discontinuation, Surgery, Drug-eluting stent, Settore MED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLARE, Observational study, medicine.symptom, Cardiology and Cardiovascular Medicine, business
Abstract

Background Drug-eluting stents (DESs) introduction has somewhat renewed the issues of strategy and stenting technique for treatment of bifurcation lesions. In particular, concerns remain on extensive use of DESs, especially in the side branch, and on time of dual antiplatelet therapy (DAT) discontinuation, reflecting lack of pertinent long-term data. This study aimed to evaluate clinical safety and efficacy of different strategies for bifurcations treatment in a large observational real-world registry. Methods A multicenter, retrospective Italian study of consecutive patients undergoing bifurcation percutaneous coronary intervention between January 2002 and December 2006 was performed. The primary end point was the long-term rate of major adverse cardiac events (MACEs). The role of DAT length on outcome was also analyzed. Results A total of 4,314 patients (4,487 lesions) were enrolled at 22 independent centers. In-hospital procedural success rate was 98.7%. After median follow-up of 24 months, MACEs occurred in 17.7%, with cardiac death in 3.4%, myocardial infarction in 4.0%, target lesion revascularization in 13.2%, and stent thrombosis in 2.9%. Extensive multivariable analysis showed that MACEs were independently predicted by age, diabetes, renal failure, systolic dysfunction, multivessel disease, myocardial infarction at admission, restenotic lesion, bare-metal stent implantation, complex stenting strategy, and short duration of DAT. Conclusions This large study based on current clinical practice in an unselected patient population presenting with bifurcation disease and submitted to percutaneous coronary intervention demonstrated favorable long-term clinical results in this challenging patient setting, especially when DESs, simple stenting strategy, and DAT for at least 6 months are used.

Published
2010

35. The inflammatory abdominal aortic aneurysm and coronary artery disease. Case report and review

Author

Ines Monte, Capodanno D, Licciardi S, Ferraro C, Mt, Giannone, Grasso S, and Nicolosi E

Subjects
Male, myocardial infarction, Aortitis, Humans, Middle Aged, aortic aneurysm, biological markers, Aortic Aneurysm, Abdominal
Abstract

Inflammatory abdominal aortic aneurysm (IAAA) is defined as an unusually thickened aneurysmatic wall, encircled by a wide dense perianeurysmal and/or retroperitoneal fibrosis with adjacent tissues adhesion, and is now considered as an extreme shape of the common phlogistic process involved in atherosclerotic plaque formation. Latest studies demonstrated that inflammation plays an important role in coronary disease and in other atherosclerosis manifestations. We introduce the clinical case of a patient with IAAA who developed an acute myocardial infarction 6 months after the surgical procedure on the aorta. Through a literature review about IAAA we stress the clinical usefulness of the inflammatory markers as independent predictors in management of patients with coronary disease and we present the hypothesis, related to the introduced case, of an advanced coronary disease, aggravated or clinically revealed after the cytokine storm related to important localized inflammatory engagements or great vascular surgery treatments.

Published
2006

36. The usefulness of clinical indexes in the evaluation of cardiovascular risk in non cardiac surgery

Author

Ga, Caruso, Capodanno D, Mt, Giannone, Giannazzo D, Ines Monte, Nigro P, and Sorrentino F

Subjects
Adult, Aged, 80 and over, Male, perioperative complications, non-cardiac surgery, Middle Aged, Risk Assessment, Severity of Illness Index, Postoperative Complications, Cardiovascular Diseases, Risk Factors, Surgical Procedures, Operative, Preoperative Care, evaluation indexes, Humans, Female, Aged, Retrospective Studies
Abstract

The preoperative cardiac evaluation of a patient who undergoes noncardiac surgery is a very important problem, particularly for diagnostic tools used. Aim of this study is to test the usefulness of 4 most used clinical indexes for the evaluation of cardiovascular risk in the management of patients who undergo noncardiac surgery.The study is based on a retrospective analysis of a group of 45 patients, who underwent extracardiac surgery in biennium 2002-2004. The cardiovascular risk scores of Goldman, Detsky, Lee and Eagle were used; a comparison among the different scores was done.Six out of our 45 patients had perioperative cardiovascular complications, and 4 of them died. The Eagle and Lee scores were more predictive than Goldman and Detsky ones. About the 13 echocardiographic tests recorded, no one of them modified the patient preoperative risk.In the preoperative assessment of risk, the Eagle score was more useful than the others ones and improved the negative predictive value of the Goldman and Detsky scores. The preventive application of the clinical indexes allows optimizing the preoperative stratification of the risk, limiting the request of useless examinations and offering to the patient a well appropriated preoperative management, reducing the incidence of complications.

Published
2006

42. ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2—care pathways, treatment, and follow-up

Author

Baigent, C., Windecker, S., Andreini, D., Arbelo, E., Barbato, E., Bartorelli, A.L., Baumbach, A., Behr, E.R., Berti, S., Bueno, H., Capodanno, D., Cappato, R., Chieffo, A., Collet, J.P., Cuisset, T., Simone, G. de, Delgado, V., Dendale, P., Dudek, D., Edvardsen, T., Elvan, A., Gonzalez-Juanatey, J.R., Gori, M., Grobbee, D., Guzik, T.J., Halvorsen, S., Haude, M., Heidbuchel, H., Hindricks, G., Ibanez, B., Karam, N., Katus, H., Klok, F.A., Konstantinides, S.V., Landmesser, U., Leclercq, C., Leonardi, S., Lettino, M., Marenzi, G., Mauri, J., Metra, M., Morici, N., Mueller, C., Petronio, A.S., Polovina, M.M., Potpara, T., Praz, F., Prendergast, B., Prescott, E., Price, S., Pruszczyk, P., Rodriguez-Leor, O., Roffi, M., Romaguera, R., Rosenkranz, S., Sarkozy, A., Scherrenberg, M., Seferovic, P., Senni, M., Spera, F.R., Stefanini, G., Thiele, H., Tomasoni, D., Torracca, L., Touyz, R.M., Wilde, A.A., Williams, B., European Soc Cardiology, Behr, Elijah/0000-0002-8731-2853, BUENO, HECTOR/0000-0003-0277-7596, Rodriguez-Leor, Oriol/0000-0003-2657-5657, Karam, Nicole/0000-0002-3861-6914, Williams, Bryan/0000-0002-8094-1841, Baigent, Colin, Windecker, Stephan, Andreini, Daniele, Arbelo, Elena, Barbato, Emanuele, Bartorelli, Antonio L., Baumbach, Andreas, Behr, Elijah R., Berti, Sergio, Bueno, Hector, Capodanno, Davide, Cappato, Riccardo, Chieffo, Alaide, Collet, Jean-Philippe, Cuisset, Thomas, de Simone, Giovanni, Delgado, Victoria, DENDALE, Paul, Dudek, Dariusz, Edvardsen, Thor, Elvan, Arif, Gonzalez-Juanatey, Jose R., Gori, Mauro, Grobbee, Diederick, Guzik, Tomasz J., Halvorsen, Sigrun, Haude, Michael, HEIDBUCHEL, Hein, Hindricks, Gerhard, Ibanez, Borja, Karam, Nicole, Katus, Hugo, Klok, Fredrikus A., Konstantinides, Stavros, V, Landmesser, Ulf, Leclercq, Christophe, Leonardi, Sergio, Lettino, Maddalena, Marenzi, Giancarlo, Mauri, Josepa, Metra, Marco, Morici, Nuccia, Mueller, Christian, Petronio, Anna Sonia, Polovina, Marija M., Potpara, Tatjana, Praz, Fabien, Prendergast, Bernard, Prescott, Eva, Price, Susanna, Pruszczyk, Piotr, Rodriguez-Leor, Oriol, Roffi, Marco, Romaguera, Rafael, Rosenkranz, Stephan, Sarkozy, Andrea, Scherrenberg, Martijn, Seferovic, Petar, Senni, Michele, Spera, Francesco R., Stefanini, Giulio, Thiele, Holger, Tomasoni, Daniela, Torracca, Lucia, Touyz, Rhian M., Wilde, Arthur A., Williams, Bryan, Cardiology, ACS - Heart failure & arrhythmias, Bern University Hospital [Berne] (Inselspital), Centro Cardiologico Monzino [Milano], Dpt di Scienze Cliniche e di Comunità [Milano] (DISCCO), Università degli Studi di Milano [Milano] (UNIMI)-Università degli Studi di Milano [Milano] (UNIMI)-Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS), 'Federico II' University of Naples Medical School, St George's, University of London, Fondazione Toscana Gabriele Monasterio, Hospital Universitario 12 de Octubre [Madrid], Centro Nacional de Investigaciones Cardiovasculares Carlos III [Madrid, Spain] (CNIC), Instituto de Salud Carlos III [Madrid] (ISC), University of Catania [Italy], IRCCS San Raffaele Scientific Institute [Milan, Italie], Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases [IHU ICAN], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Institut de Cardiométabolisme et Nutrition = Institute of Cardiometabolism and Nutrition [CHU Pitié Salpêtrière] (IHU ICAN), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital de la Timone [CHU - APHM] (TIMONE), Leiden University Medical Center (LUMC), Hasselt University (UHasselt), Jessa Ziekenhuis [Hasselt], Uniwersytet Jagielloński w Krakowie = Jagiellonian University (UJ), Oslo University Hospital [Oslo], Paris-Centre de Recherche Cardiovasculaire (PARCC (UMR_S 970/ U970)), Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPC), CHU Pontchaillou [Rennes], Laboratoire Traitement du Signal et de l'Image (LTSI), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM), University College of London [London] (UCL), Università degli Studi di Milano = University of Milan (UNIMI)-Università degli Studi di Milano = University of Milan (UNIMI)-Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS), Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases (ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Universiteit Leiden, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM), SCHERRENBERG, Martijn, Torracca, Luccia, Cardiology, Task Force for the management of COVID-19 of the European Society of, European Soc Cardiology, and Task Force for the management of COVID-19 of the European Society of Cardiology

Subjects
medicine.medical_specialty, COVID-19/diagnosis, Coronavirus disease 2019 (COVID-19), Physiology, [SDV]Life Sciences [q-bio], ACE2, Heart failure, Disease, Acute coronary syndromes, Arrhythmias, Pulmonary embolism, Thrombosis, Special Article, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Physiology (medical), Non-invasive imaging, Pandemic, Humans, Medicine, AcademicSubjects/MED00200, Prospective Studies, shock, COVID-19, Myocarditis, Venous thromboembolism, Intensive care medicine, Pandemics, Cardiogenic shock, Cardiovascular Diseases/diagnosis, business.industry, Biomarkers, Cardiogenic, Cardiovascular Diseases, Myocardial injury, Critical Pathways, Human medicine, Cardiology and Cardiovascular Medicine, business, Follow-Up Studies
Abstract

Aims Since its emergence in early 2020, the novel severe acute respiratory syndrome coronavirus 2 causing coronavirus disease 2019 (COVID-19) has reached pandemic levels, and there have been repeated outbreaks across the globe. The aim of this two part series is to provide practical knowledge and guidance to aid clinicians in the diagnosis and management of cardiovascular (CV) disease in association with COVID-19. Methods and results A narrative literature review of the available evidence has been performed, and the resulting information has been organized into two parts. The first, which was reported previously, focused on the epidemiology, pathophysiology, and diagnosis of CV conditions that may be manifest in patients with COVID-19. This second part addresses the topics of: care pathways and triage systems and management and treatment pathways, both of the most commonly encountered CV conditions and of COVID-19; and information that may be considered useful to help patients with CV disease (CVD) to avoid exposure to COVID-19. Conclusion This comprehensive review is not a formal guideline but rather a document that provides a summary of current knowledge and guidance to practicing clinicians managing patients with CVD and COVID-19. The recommendations are mainly the result of observations and personal experience from healthcare providers. Therefore, the information provided here may be subject to change with increasing knowledge, evidence from prospective studies, and changes in the pandemic. Likewise, the guidance provided in the document should not interfere with recommendations provided by local and national healthcare authorities., Graphical Abstract Graphical Abstract

Full Text
View/download PDF

48. Treatment strategies for coronary in-stent restenosis.

Author

Giacoppo, D., Gargiulo, G., Aruta, P., Capranzano, P., Tamburino, C., and Capodanno, D.

Subjects
MYOCARDIAL revascularization, CORONARY restenosis, TREATMENT effectiveness, DRUG-eluting stents
Abstract

The article focuses on interventional treatments for coronary in-stent restenosis. Topics mentioned include an overview of interventional treatments identified including bare metal stents, brachytherapy, and rotational atheroctomy, target lesion revascularisation and late lumen loss as primary endpoints of the study, and association between drug eluting stents and superior clinical outcomes.

Published
2015

49. Cardiovascular Magnetic Resonance for the Assessment of Patients undergoing Transcatheter Aortic Valve Implantation: A Pilot Study.

Author

La Manna A, Sanfilippo A, Capodanno D, Salemi A, Polizzi G, Deste W, Cincotta G, Cadoni A, Marchese A, Figuera M, Ussia GP, Pittala R, Privitera C, and Tamburino C.

Abstract

BACKGROUND: Before trans-catheter aortic valve implantation (TAVI), assessment of cardiac function and accurate measurement of the aortic root are key to determine the correct size and type of the prosthesis. The aim of this study was to compare cardiovascular magnetic resonance (CMR) and trans-thoracic echocardiography (TTE) for the assessment of aortic valve measurements and left ventricular function in high-risk elderly patients submitted to TAVI. METHODS: Consecutive patients with severe aortic stenosis and contraindications for surgical aortic valve replacement were screened from April 2009 to January 2011 and imaged with TTE and CMR. RESULTS: Patients who underwent both TTE and CMR (n = 49) had a mean age of 80.8+/-4.8 years and a mean logistic EuroSCORE of 14.9+/-9.3 %. There was a good correlation between TTE and CMR in terms of annulus size (R2=0.48, p<0.001), left ventricular outflow tract (LVOT) diameter (R2 =0.62, p<0.001) and left ventricular ejection fraction (LVEF) (R2=0.47, p<0.001) and a moderate correlation in terms of aortic valve area (AVA) (R2=0.24, p<0.001). CMR generally tended to report larger values than TTE for all measurements. The Bland-Altman test indicated that the 95% limits of agreement between TTE and CMR ranged from -5.6 mm to +1.0 mm for annulus size, from -0.45 mm to +0.25 mm for LVOT, from -0.45 mm2 to +0.25 mm2 for AVA and from -29.2% to 13.2% for LVEF. CONCLUSIONS: In elderly patients candidates to TAVI, CMR represents a viable complement to transthoracic echocardiography. [ABSTRACT FROM AUTHOR]

Published
2011

Catalog

Books, media, physical & digital resources
See catalog results